BIIB Biogen Inc.: EV/EBITDA Multiple
Biogen Inc. is actively acquiring licenses and small laboratories to fill gaps in its own R&D. The operating model relies on large-scale outsourcing of clinical trials and logistics. The change in the EV/EBITDA ratio on GURU.Markets is available for analysis, where the 16.97 mark serves as a key metric. This confirms a diversification strategy toward immunology and rare genetic pathologies.
Comprehensive metric breakdowns and analytics for biogen.com (BIIB)
- market price and analyst price targets:
- company stock capitalization data:
- issuer book value statistics:
- debt and liquidity details:
Total Debt to Equity Ratio Biogen Inc.|BIIB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Biogen|BIIB - Company Total Debt Obligations|Debt to Book Capitalization Ratio Biogen Idec|BIIB - Company Long-Term Indebtedness|Company Short-Term Debts Biogen|Quick Liquidity Indicator biogen.com
- financial results and valuation multiples details:
BIIB - Net Financial Result|Projected Future Earnings Biogen Inc.|BIIB - Price to Earnings Ratio|Forward P/E Multiple Biogen Inc.|BIIB - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Biogen Idec|BIIB - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Biogen|BIIB - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months biogen.com|BIIB - Earnings per share growth this year|Earnings growth forecast for next year Biogen Inc.
Comprehensive company analysis:BIIB (Biogen Corp)
The EV/EBITDA multiple compares the total enterprise value of the business, including net debt, with operating profit before taxes and amortization. For Biogen Inc. (BIIB), this calculation is critical when assessing the risks of patent expiration and the uncertainty surrounding new developments. By analyzing the company's EV-to-EBITDA ratio over a time series, an investor can identify overpayment for the asset during periods of speculation. A steady decline in this indicator confirms the fundamental undervaluation of the business.
Competitor analysis for Biogen Inc.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurocrine Biosciences Inc NBIX|Regencell Corp (RGC) - Company Value to EBITDA|Axsome Therapeutics - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple acadia-pharm.com (ACAD)|XENE: EV/EBITDA Multiple|Company Value to EBITDA Viking Therapeutics Inc (VKTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Supernus Pharma|Enterprise Value to Operating Income Before Depreciation CPRX (Catalyst Corp)|Enterprise Value to EBITDA Ratio DNLI (Denali Therapeutics)|HRMY (harmonybiosciences.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BHVN (Biohaven)|Total Company Value to Operating Income Before Depreciation Ratio Amylyx Pharmaceuticals Inc (AMLX)|TRVI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRAX (Praxis Corp) - Enterprise Value to Operating Income Before Depreciation|AVXL: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ceribell.com|Enterprise Value to EBITDA Ratio PRTA|Alector Therapeutics (ALEC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANNX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OMER (omeros.com)|EV/EBITDA Multiple NGNE (Neurogene Inc.)|Total Company Value to Operating Income Before Depreciation Ratio acimmune.com (ACIU)|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Neumora NMRA|SCLX: EV/EBITDA Multiple|TVGN (Tevogen Bio Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alpha Cognition Inc|Enterprise Value to Operating Income Before Depreciation CGTX (cogrx.com)|EV/EBITDA Multiple IKT|SAVA - Company Value to EBITDA|Assertio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Coya Therapeutics Inc COYA|VTGN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation OVID (Ovid Therapeutics Inc.)|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA CervoMed, Inc. (CRVO)|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|Annovis Bio Inc (ANVS) - Company Value to EBITDA|Grace Tx - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Firefly Neuro (AIFF)|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|HSDT (heliusmedical.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Total Company Value to Operating Income Before Depreciation Ratio Neuphoria Therapeutics, Inc. (NEUP)|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Alzamend Neuro|Enterprise Value to EBITDA Ratio CYCN|Protagenic (PTIX) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KTTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRGT (cortigent.com)|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|Total Company Value to Operating Income Before Depreciation Ratio BrainStorm Cell Therapeutics Inc. (BCLI)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|ELYM: EV/EBITDA Multiple|ITCI (Intra-Cellular Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Enterprise Value to Operating Income Before Depreciation MRNS (Marinus Pharma)|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|Sage Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA cerevel.com (CERE)
